SKYE Q3'26 Earnings: EPS estimate is (1.14) USD

What happened

Skye Bioscience is scheduled to report Q3'26 results on November 5, with disclosure expected at 7:00 AM ET. The supplied headline gives an estimated loss per share of (1.14) USD, while the revenue estimate is 0 USD.

Confirmed

Global impact / market context

The estimates set expectations for Skye Bioscience’s upcoming report: revenue is forecast at zero and the expected loss per share is (1.14) USD. Reported results above or below those estimates could change investors’ view of the company’s ability to generate sales and limit losses.

Analyst inference

The article lists earlier quarterly loss-per-share estimates and reported results, but provides no revenue figures, company guidance, or explanation for the forecasts. Investors therefore have limited context here to assess the business outlook or determine what could drive a difference from estimates.

Analyst inference

What to watch

1. Check the November 5 results for reported revenue and earnings per share, the company’s profit or loss allocated to each share, against the supplied estimates. Confirmed
2. Look for company comments on sales plans, spending, or cash available; the supplied article gives no guidance explaining the zero revenue estimate or expected loss. Analyst inference
3. Compare the reported loss per share with the (1.14) USD estimate; a narrower or wider loss could shift investor expectations for Skye Bioscience’s financial progress. Analyst inference

Evidence

• Original source link unavailable